Transurethral electrovaporization of the prostate (TUVP) is one of the alternative, minimally invasive procedures to treat BPH with promising initial results. We reviewed the available English literature to evaluate the long-term safety, efficacy and durability of TUVP using various vaporizing electrodes. We performed a MEDLINE keyword search and assessed all prospective randomized studies, which compared TUVP to standard transurethral resection of the prostate (TURP) that reached 1 y follow-up. Data were analysed for improvement of IPSS and Q max , operation time, hospital stay, perioperative bleeding, postoperative irritative symptoms, long-term side effects and reoperation rate. We reviewed a total of 244 TUVP compared to 259 TURP patients in six prospective randomized studies that reached 1 y follow-up. Less perioperative bleeding, shorter catheterization time (mean of TUVP: 30 h vs TURP: 61 h) and shorter hospital stay (mean of 1.4 days vs TURP: 3.4 days) were reported in the TUVP patients. The improvement in IPSS (71%) and mean Q max (20 ml/s) was similar in both groups. The reoperation rate was 2% per year in both vaporization and resection patients. In conclusion, analysis of the prospective randomized trials that reached 1 year follow-up revealed that TUVP is as effective as standard TURP in the treatment of BPH. Long-term side effects and reoperation rates are comparable and the initial improvement was maintained over 1 year for the majority of patients.
Introduction
Transurethral resection of the prostate (TURP) is still the most popular operation for symptomatic BPH. During 1995, 5.8 per 1000 men aged 55 y and over in the US and 5.5 per 1000 men aged 45 y and over in the UK underwent TURP. 1 The Agency for Health Care Policy and Research Review (AHCPR) suggested that the subjective success rate after TURP is 88% 2 and the UK National Prostatectomy Audit (NPA) suggested a 64% symptomatic improvement after TURP. 3 Nevertheless, the morbidity rates associated with TURP vary from 7 to 43% in the AHCPR and from 10 to 35% in the NPA. These complications include perioperative bleeding, TUR syndrome, incontinence, retrograde ejaculation and impotence. [2] [3] [4] [5] TURP is also associated with relatively long hospital stay (3-5 days), [2] [3] [4] which adds to the costs of the procedure. These complications, as well as the high costs associated with prolonged hospitalization, have fuelled the interest to develop alternative surgical procedures that may be as good as TURP in relieving the obstruction by removing prostatic tissue, in addition to reducing morbidity, hospital stay and eventually cost.
Transurethral electrovaporization of the prostate (TUVP), a modification of existing transurethral technology, is the most recent promising alternative to TURP. This was first described by Bush et al 6 in 1993, who used a grooved ball electrode and pure cutting current to sculpt out the prostatic bed, and claimed advantages of little or no bleeding, fluid absorption or electrolyte imbalance. Subsequently, Kaplan and Te 7 in 1995, published the first peer-review study describing their early experience with TUVP demonstrating efficacy and safety in 25 men with mild-to-moderate bladder outflow symptoms.
The most extensively studied instrument for electrovaporization is the VaporTrode s , a grooved electrode from Circon s , ACMI (Figure 1) . Recently, three studies using a spiked electrode from Storz s were published with encouraging early reports on efficacy, safety and durability equal to TURP. 8 Tewari and Narayan 9 in 1996, Te and Kaplan 10 in 1997 and more recently Patel et al 11 reviewed the electrosurgical principles of prostate vaporization and reported on the early clinical results. The purpose of this paper is to update and review the long-term follow-up of the prospective randomized trials on TUVP, which reached at least 1 year of follow-up.
Assessment of unseen heat damage during prostate vaporization
There has been a concern of potential damage to the vital periurethral structures as a result of using high cutting current during electrovaporization. Perlmutter et al 12 in 1995 demonstrated in a living canine model that coagulation depth does increase with higher wattage and multiple passes of the vaporizing cylinders, not exceeding 2-3 mm deep to the vaporized cavity. They also reported temperature increases of 41C in the area up to 5 mm away from the vaporization site. The largest temperature increases were found in the irrigation fluid as it passed through the prostatic cavity, where it acts as heat sink. Clinically, Patel et al, 13 in a prospective study to assess the effects of unseen heat damage to vital periurethral structures during prostate vaporization with VaporTrode s or conventional TURP, showed that there was no significant rectal or sphincteric heating with either procedure. They concluded that neither conventional TURP nor TUVP appeared to be unsafe treatments with respect to unseen deep heating effects to vital periprostatic structures. The extra energy used during TUVP provided the benefit of improved coagulative haemostasis concurrently with tissue vaporization without compromising treatment safety.
Histopathological changes after prostate vaporization
Perlmutter et al, 14 and, more recently, Benjamin et al 15 studied the chronic histopathological changes caused by electrovaporization of the prostate in the canine models. At 1 week, the prostate cavity was lined with denuded glandular and stromal elements with acute inflammation. Re-epithelization was underway by the third postoperative week and epithelial stratification by the fifth week. There was no extension of the initial 2 mm zone of necrosis at any time examined, indicating highly localized effects of this technique. Clinically, Juma assessed the histologic changes in the prostate in 10 men with symptomatic BPH following TUVP using the roller ball. Histologically, a zone of coagulative necrosis 1-2 mm deep was seen at the base of the crater adjacent to normal prostate tissue. 16 Long-term prospective randomized trials on TUVP vs TURP
We reviewed six prospective randomized trials (PRT) comparing TUVP to TURP, which have reached 1 year follow-up. [17] [18] [19] [20] [21] [22] The dial power settings for vaporization, types of electrodes and electrosurgical generators for these studies are summarized in Table 1 .
Perioperative bleeding and fluid absorption (Table 2) In all the PRT reviewed comparing TUVP to TURP, [17] [18] [19] [20] [21] [22] there was a significant decrease in blood loss in the vaporized patients compared to the resected patients.
None of the TUVP patients required blood transfusion compared to six TURP patients (2.3%). Wasson et al 23 reported a blood transfusion rate of 1% after TURP and 
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Mebust et al 4 reported a 2.5% rate of intraoperative and 3.9% postoperative transfusion after TURP.
TUR syndrome, reported to range between 0.5% in the UK NPA 3 and 2% in AHCPR 2 after TURP, has not yet been reported after TUVP. 9, [17] [18] [19] [20] [21] [22] 24 This suggests less fluid absorption during prostatic vaporization. In a prospective randomized trial comparing TUVP (15 patients) to TURP (15 patients) using 1.5% glycine labelled with 1% ethanol irrigating solution during the operation, Cetinkaya et al 25 found that at the end of surgery, the mean fluid absorption during TUVP was significantly less than during TURP (TUVP: 672 ml vs TURP: 1347 ml, Po0.05).
Irrigation after TUVP varies from centre to centre. Hammadeh et al 17 reported that none of their TUVP patients required immediate postoperative irrigation, whereas TURP patients were irrigated with an average of 17 l of normal saline. Cetinkaya et al 20 irrigated their TUVP patients with a mean of 16 l. The rest of the PRT studies did not mention whether their TUVP patients required postoperative irrigation. 18, 19, 21, 22 Catheterization time and hospital stay ( Table 2) All six PRT prostate vaporization studies [17] [18] [19] [20] [21] [22] were associated with significantly shorter catheterization time (mean 30 h) and consequently shorter hospital stays (mean 1.4 days) compared to TURP patients (61 h and 3.4 days respectively). Catheterization time in large TURP studies varies between a mean of 3 days 4 and 4 days. 23 Only two PRT studies reported on delayed clot retention requiring recatheterization (TUVP: 6% vs TURP: 5%).
17,18
Postoperative irritative symptoms (Table 2) Postoperative irritative symptoms after TUVP were variable in incidence. 17, 18, 21, 22 Three of these studies 18, 21, 22 suggested that irritative symptoms were slightly more common postoperatively in the vaporized groups. However, most studies commented that these symptoms were of short duration and self-limiting, hence easily managed.
Efficacy and durability of TUVP (Tables 3 and 4)
In the pilot prospective nonrandomized TUVP studies that reached 1 year follow-up, there was a significant decrease in symptom score and increase in Q max , which was maintained at 1 year follow-up. 9, 24 This was confirmed in the PRT comparing prostate vaporization to resection, [17] [18] [19] [20] [21] [22] showing a comparable and durable improvement in symptom score (TUVP: 73% vs TURP: 73%) and mean Q max (TUVP: 20 ml/s vs TURP: 20 ml/s), postoperatively and up to 1 year. One of the PRT performed pressure-flow study in both TUVP and TURP patients preoperatively and postoperatively at 3 months. The detrusor pressure at peak flow reduced significantly and comparably in both groups. 19 Long-term complications of TUVP (Table 5) Incontinence after prostate surgery is a rare but serious complication. Total urinary incontinence after TURP varies between 1% in the AHCPR and 6% in the UK NPA. 2, 3 The incidence of incontinence in the six PRT comparing TUVP to TURP was 2% after TUVP (five patients: four stress incontinence and one because of sphincter damage) compared to 1% after TURP (two patients: one stress incontinence and one because of sphincter damage). [17] [18] [19] [20] [21] [22] Kupeli et al 22 reported that one patient in each arm had incontinence because of sphincter damage and Gallucci et al 19 reported stress incontinence in four patients after TUVP compared to one patient after TURP, which they attributed to the thermal damage to the sphincter during vaporization of 17, 18, 21, 22 )
31 (21) 27 (17) TUVP is effective, safe and durable MY Hammadeh and T Philp the apical tissue. However, experimental and clinical studies on TUVP demonstrated that vaporization is a safe treatment with respect to unseen deep heating effects to vital periprostatic structures and without any significant rectal or sphincteric heating.
12,13
The incidence of urethral stricture and bladder neck sclerosis after prostate vaporization is comparable to those after resection (Table 4 ). In the six PRT studies reviewed, urethral stricture incidence was 3% (seven patients) after TUVP compared to 2% (eight patients) after TURP. [17] [18] [19] [20] [21] [22] McConnell et al 2 and Wasson et al 23 reported a rate of 3% after TURP. The incidence of bladder neck sclerosis was comparable between prostate vaporization and resection in the six PRT (1% in each group) [17] [18] [19] [20] [21] [22] despite using higher cutting current during vaporization. Bladder neck sclerosis in large TURP studies varies between 1.7 2 and 3.6%. 24 The reoperation rate after TURP varies from 10% at 5 y 2 to 16% at 8 y, 25 with an approximately constant rate of 2% each year. In the reviewed PRT, the reoperation rate was 2% in each of the TUVP and TURP groups during the first year. [17] [18] [19] [20] [21] [22] However, Patel et al 11 in a recent metaanalysis review of five PRT on prostate vaporization compared to prostate resection (two of the reviewed PRT did not reach 1 y follow-up) reported 3.5% (5.5 patients) reoperation rate in each of the TUVP and TURP groups within 1 y. 11 Hammadeh et al 26 reported a reoperation rate of 13% during 3 y (approximately 4% per year) in both TUVP and TURP groups. This is so far the longest follow-up study on TUVP in the English literature.
Erectile dysfunction and retrograde ejaculation (Table 5) Only three PRT studies reported on erectile dysfunction and retrograde ejaculation. In all, 67 TUVP patients and 66 TURP patients were sexually active preoperatively in these studies. Erectile dysfunction after prostate 17, 18, 21 ) 56 (84) 56 (85) TUVP is effective, safe and durable MY Hammadeh and T Philp vaporization was higher (12%) compared to (5%) after prostate resection in the PRT. 17, 18, 21 However, the incidence of erectile dysfunction in these PRT is comparable to the large TURP studies (13.6% in the AHCPR study 2 and 31% in the recent UK NPA 3 ). Retrograde ejaculation incidence was comparable in both groups (TUVP: 84% vs TURP: 85%) 17, 18, 21 and comparable to other large TURP studies.
2,3

TUVP does not provide tissue for histopathological examination
One of the drawbacks of TUVP is that prostate vaporization does not provide tissue for histological examination. Therefore, the incidental finding of prostate cancer, which is historically present in approximately 10% of men having TURP for apparently benign disease, may be missed. All the patients in the reviewed PRT had DRE and PSA, showing a benign prostate. Patients with clinical evidence of prostate malignancy were excluded from the studies. However, Gallucci et al 19 reported an incidental finding of prostate cancer in 6% of the patients who underwent TURP despite these measures. This issue of incidental finding of prostate cancer may be overcome by obtaining a prostate chip for histological examination using the standard loop before starting the vaporization.
Is TUVP suitable for prostates larger than 60 g?
In all the PRT reviewed, the size of the prostate was less than 60 g. Although vaporization is suitable for larger prostates, it takes longer to vaporize these prostates than to resect them. Some authors 27 suggested the use of the 'sandwich technique therapy' for prostates larger than 60 g where they initially performed vaporization using smooth roller electrode followed by resection with standard loop for rapid tissue removal, and finally the use of the roller electrode for haemostasis. Others 28 used a modified loop resection followed by electrovaporization to achieve optimal results for prostates larger than 40 g. Unfortunately, there are no prospective randomized trials to compare prostate vaporization to resection in prostates larger than 60 g.
Conclusion
The review of cohort prospective studies on TUVP vs TURP, which reached 1 year follow-up, shows that TUVP is clinically as effective as TURP for the relief of obstruction caused by enlarged benign prostatic hypertrophy with similar durability.
TUVP offers some distinct advantages. The use of established instruments reduces the start-up cost. The decreased perioperative bleeding and reduced catheterization time lead to shorter hospital stay. Hence, there are obvious financial and health benefits to both patients and institutions.
We feel that the technique of electrovaporization of the prostate promises to set new standards in the treatment of BPH, at least for small-to-moderate size prostates and those patients at high risk of bleeding. Therefore, large numbers of patients with long-term multicentre randomized trials are required to confirm that.
